VitriVax

Boulder, United States

VitriVax is a formulation technology company that engineers solutions to maximize the accessibility and utility of human vaccines.

$17.3M raised

Oct 2025

Series B

Top Investors

RA Capital ManagementBill & Melinda Gates FoundationAdjuvant Capital

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has VitriVax raised?

VitriVax has raised $17.3M in total funding. The most recent round was Series B. The last funding was announced in October 2025.

Who are VitriVax's investors?

VitriVax's investors include RA Capital Management, Bill & Melinda Gates Foundation, Adjuvant Capital.

Where is VitriVax headquartered?

VitriVax is headquartered in Boulder, United States.

What does VitriVax do?

VitriVax is a formulation technology company that engineers solutions to maximize the accessibility and utility of human vaccines.

What stage is VitriVax at?

VitriVax is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated October 22, 2025.

MLA

"VitriVax — Funding & Investors." VCBacked, October 22, 2025, https://www.vcbacked.co/company/vitrivax. Accessed June 3, 2026.

APA

VCBacked. (2025). VitriVax — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/vitrivax

Wikipedia (cite web)

{{cite web |title=VitriVax — Funding & Investors |url=https://www.vcbacked.co/company/vitrivax |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated October 22, 2025.